Association of anticardiolipin antibodies with preeclampsia: A systematic review and meta-analysis

Obstetrics and Gynecology

Volumn 116, Issue 6, 2010, Pages 1433-1443

  Do Prado, Aline D ^a   Piovesan, Deise M ^b   Staub, Henrique L ^b   Horta, Bernardo L ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

AUTOIMMUNE DISEASE; BLOOD PRESSURE; CASE CONTROL STUDY; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEDLINE; META ANALYSIS; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 78650133588     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181fe02ec     Document Type: Review

References (92)

1. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospho-lipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospho-lipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614-20.
4. Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003;1:111.
5. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066-74.
6. Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
7. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe pre-eclampsia. Obstet Gynecol 1989;73:541-5.
8. Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H, PETRA-Investigators. Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy. Hypertens Pregnancy 2007;26:433-45.
9. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995;86(4 Pt 1):555-9.
10. Briones-Garduño JC, Diaz de León-Ponce M, Barrios-Prieto E, Salazar-Exaire JD. [IgM antiphospholipical antibodies in pre-eclampsia- eclampsia]. Cir Cir 2003;71:449-54.
11. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol 2003;102:294-300.
12. Branch DW, Porter TF, Rittenhouse L, Caritis S, Sibai B, Hogg B, et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001;184:825-32; discussion 832-4.
13. Valdés-Macho E, Cabiedes J, Villa AR, Cabral AR, Alarcó n-Segovia D. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res 2002;33:460-5.
14. von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb Res 2000;100:363-5.
15. Heilmann L, Schneider DM, von Tempelhoff GF, Kuse S. Antiphospholipid- antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP-syndrome. Geburtshilfe Und Frauenheilkunde 2000; 60:95-100.
16. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies and pre-eclampsia: a case-control study. Obstet Gynecol 2001;97: 29-34.
17. Nestorowicz B, Ostanek L, Ronin-Walknowska E, Fiedor-owicz-Fabrycy I, Skoczowska M, Czajkowska E, et al. [Antiphospholipid antibodies in high-risk pregnancy]. Ginekol Pol 2000;71:500-8.
18. Martínez-Abundis E, González-Ortiz M, Cortés-Llamas V, Salazar-Páramo M. Anticardiolipin antibodies and the severity of preeclampsia-eclampsia. Gynecol Obstet Invest 1999;48: 168-71.
19. Fialová L, Kalousová M, Soukupová J, Malbohan I, Madar J, Frisová V, et al. Markers of inflammation in preeclampsia. Prague Med Rep 2004;105:301-10.
20. Kurki T, Ailus K, Palosuo T, Ylikorkala O. Antibodies to oxidized low-density lipoprotein, cardiolipin, and phosphati-dyl serine fail, to predict the risk of preeclampsia. Hypertens Pregnancy 1996;15:251-6.
21. Taylor PV, Skerrow SM, Redman CW. Pre-eclampsia and anti-phospholipid antibody. Br J Obstet Gynaecol 1991;98: 604-6.
22. D'Anna R, Scilipoti A, Leonardi J, Scuderi M, Jasonni VM, Leonardi R. Anticardiolipin antibodies in pre-eclampsia and intrauterine growth retardation. Clin Exp Obstet Gynecol 1997;24:135-7.
23. Allen JY, Tapia-Santiago C, Kutteh WH. Antiphospholipid antibodies in patients with preeclampsia. Am J Reprod Immunol 1996;36:81-5.
24. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200:46 e1-5.
25. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T, et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005;46:1270-4.
26. Harris EN, Hughes GR. Standardising the anti-cardiolipin antibody test. Lancet 1987;1:277.
27. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
28. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
29. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321-59.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
32. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21: 1559-73.
33. Faden D, Tincani A, Tanzi P, Spatola L, Lojacono A, Tarantini M, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73:37-42.
34. Bowen RS, Moodley J, Dutton MF, Fickl H. Antibodies to oxidised low-density lipoproteins and cardiolipin in pre-eclampsia and eclampsia. J Obstet Gynaecol 2002;22:123-6.
35. Harris EN, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165(5 Pt 1):1272-7.
36. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic throm-bophilic mutations. Obstet Gynecol 2000;96:45-9.
37. Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993;100:909-13.
38. Bendon RW, Hayden LE, Hurtubise PE, Getahun B, Siddiqi TA, Glueck HI, et al. Prenatal screening for anticardiolipin antibody. Am J Perinatol 1990;7:245-50.
39. Andelová K, Su?la K, Velebil P. [Importance of anticardiolipin antibody screening in pregnancy]. Ceska Gynekol 1998, 63 446-9.
40. Figueiro-Filho EA, Oliveira VM. Association of recurrent abortion, fetal loss and severe pre-eclampsia with hereditary thrombophilias and antiphospholipid antibodies in pregnant women of central Brazil. Revista Brasileira de Ginecol Obstet 2007;29:561-7.
41. Gomez Jimenez JM, Garcia HI, Gallego JG, Galeano AQ, Restrepo CM, Aguirre N. Asociacion entre anticardiolipina y anti b2 glicoproteina I con preeclampsia antes de las 35 semanas de gestacion. Revista Colombiana de Obstet Ginecol 2001;52:60-6.
42. Briones Garduño JC, Díaz de León Ponce MA, Irigoyen CL, Martínez Baez L, Briones Vega CG, Urrutia Torres F. Anticu-erpos anticardiolipina en la preeclampsia/eclampsia. Rev Asoc Mex Med Crit Ter Int 1997;11:194-6.
43. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol 2001;97(5 Pt 1):753-9.
44. Barbarino-Monnier P, Gobert B, Ribon AM, Schweitzer M, Faure GC, Bene MC. [Isotypic surveillance of anti-cardiolipin antibodies and high risk pregnancies]. J Gynecol Obstet Biol Reprod (Paris) 1997;26(suppl 3):164-5. (Pubitemid 27517554)
45. Rueda Merlano ML. Anticuerpos antifosfolipideos y su rela-cion con la hipertension inducida por el embarzo preeclampsia [Revisão]. Santafe de Bogota: Escuela Colombiana de Medicina-Faculta de Medicina; 1995.
46. Birdsall M, Pattison N, Chamley L. Antiphospholipid antibodies in pregnancy. Aust N Z J Obstet Gynaecol 1992;32:328-30.
47. El-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am J Obstet Gynecol 1991; 164(5 Pt 1):1253-61.
48. Hossain N, Shamsi T, Soomro N. Frequency of thrombophilia in patients with adverse pregnancy outcome. J Pak Med Assoc 2005;55:245-7.
49. Kaleli B, Kaleli I, Aktan E, Turan C, Akşit F. Antiphospholipid antibodies in eclamptic women. Gynecol Obstet Invest 1998; 45:81-4.
50. Karpov N, Baranov AA, Shilkina NP, Nasonov EL, Aleksan-drov SE, Abaitova NE, et al. [Cardiolipin antibodies in pregnancy of high risk]. Klin Med (Mosk) 1999;77:19-22.
51. Katano K, Aoki A, Sasa H, Ogasawara M, Matsuura E, Yagami Y. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996;11:509-12.
52. Kouassi D, Diafouka F, Sawadogo GD, Amari S, Kone M, Monnet D, et al. [Antiphospholipid antibodies in African women presenting obstetrical complications]. Ann Biol Clin (Paris) 2004;62:213-5.
53. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
54. Lynch A, Byers T, Emlen W, Rynes D, Shetterly SM, Ham-man RF. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstet Gynecol 1999;93: 193-8.
55. Matthiesen LS, Berg G, Ernerudh J, Skogh T. A prospective study on the occurrence of autoantibodies in low-risk pregnancies. Eur J Obstet Gynecol Reprod Biol 1999;83:21-6.
56. Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. S Afr Med J 1995;85:105-7.
57. Ogunyemi D, Ku W, Arkel Y. The association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein A levels with obstetrical complications in pregnancy. J Thromb Thrombolysis 2002;14:157-62.
58. Parry S, Macones GA, Roth NW, Desperito TJ, Marzullo A, Morgan MA. Antiphospholipid antibodies in chronic hypertension: the value of screening during pregnancy. Am J Perinatol 1998;15:527-31.
59. Nodler J, Moolamalla SR, Ledger EM, Nuwayhid BS, Mulla ZD. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth 2009;9:11.
60. Queyrel V, Ducloy-Bouthors AS, Michon-Pasturel U, Hachulla E, Dubucquoi S, Caron C, et al. [Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women]. Rev Med Interne 2003;24:158-64.
61. Rajewski M, Skrzypczak J. [Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]. Pol Arch Med Wewn 2006;115:417-25.
62. Rao AA, Ananthakrishna NC. Anticardiolipin antibodies in eclampsia. Int J Gynaecol Obstet 1992;38:37-40.
63. Scott RA. Anti-cardiolipin antibodies and pre-eclampsia. Br J Obstet Gynaecol 1987;94:604-5.
64. Stuart RA, Kornman LH, McHugh NJ. A prospective study of pregnancy outcome in women screened at a routine antenatal clinic for anticardiolipin antibodies. Br J Obstet Gynaecol 1993;100:599-600.
65. Ulcová-Gallová Z, Bouse V, Krizanovská K, Balvín M, Rokyta Z, Netrvalová L. Beta 2-glycoprotein I is a good indicator of certain adverse pregnancy conditions. Int J Fertil Womens Med 2001;46:304-8.
66. Uncu G, Ozan H, Küçükerdog?an I, Cengiz C. Anticardiolipin antibodies in pregnancy induced hypertension. Eur J Obstet Gynecol Reprod Biol 1996;70:97-100.
67. Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009;79:188-95.
68. Yamamoto T, Yoshimura S, Geshi Y, Sasamori Y, Okinaga S, Kobayashi T, et al. Measurement of antiphospholipid antibody by ELISA using purified beta 2-glycoprotein I in preeclampsia. Clin Exp Immunol 1993;94:196-200.
69. Zeeman GG, Alexander JM, McIntire DD, Leveno KJ. The significance of antiphospholipid antibodies in pregnant women with chronic hypertension. Am J Perinatol 2004;21:275-9.
70. Zendejas Cervantes LH, Romero Romero H, Lechuga Martín del Campo A, Lechuga Martín del Campo D, de la Rosa Bayón J, Castrejón Vázquez MI, et al. [Preeclampsia-eclamp-sia: a change in utero-placental microcirculation. Immuno-logic, histologic, and biochemical features]. Rev Alerg Mex 2002;49:80-6.
71. Rajah SB, Moodley J, Pudifin D, Duursma J. Anticardiolipin antibodies in hypertensive emergencies in pregnancy. Clinical and experimental hypertension part B. Hypertens Pregnancy 1990;9:267-71.
72. Baptista-González HA, Rosenfeld-Mann F, Saavedra-Trejo MR, Castro-Ló pez JL, Peñ uela-Olaya MA. [Changes in the thrombophilic status in patients with pre-eclampsia]. Ginecol Obstet Mex 1999;67:176-82.
73. Vasquez DSD, De Zubiria A, Henao S, Martinez K. Relacion existente entre anticuerpos antifosfolipideos y preeclampsia. Revista Colombiana de Obstet Ginecol 1996;47:181-4.
74. Andrade M, Alvaro R, Sekler E. Anticuerpos fosfolipídeos: frecuencia en preeclampsia y otros estados hipertensivos del embarazo. Medicina Intern (Caracas) 1997;13:219-26.
75. Da Silva MA, Mendez MM. Preeclampsia y anticuerpos anticardiolipina. Caracas: Universidad Central de Venezuela; 1998.
76. Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:159-67.
77. Pritchard JA, MacDonald PC, Gant NF. Williams Obstetrics. 17th ed. Norwalk (CT): Appleton-Century-Crofts; 1985.
78. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
79. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG Technical Bulletin 219. Washington, DC: ACOG; 1996.
80. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988;158:892-8.
81. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheu-matol 2006;33:2214-21.
82. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am J Psychiatry 2007;164:942-8.
83. Harris EN, Mackworth-Young CG, Gharavi AE, Patel BM, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;322:1211-4.
84. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
85. Jüni P, Altman D, Egger M. Assessing the quality of randomized controlled trials. In: Egger M, Smith GD, Altman D, editors. Systematic reviews in health care meta-analysis in context. 2nd ed. London (UK): BMJ Books; 2001. p. 87-108.
86. Comparsi AB PdCB, Poli de Figueiredo CE, Paula LG. Pré- eclâmpsia: diagnó stico e tratamento. Acta Médica 2001;22: 293-309.
87. Harlow FH, Brown MA. The diversity of diagnoses of pre-eclampsia. Hypertens Pregnancy 2001;20:57-67.
88. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for pre-eclampsia. Obstet Gynecol 2004;104:1367-91.
89. Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads CA, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009;88: 758-65.
90. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
91. Odegård RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Risk factors and clinical manifestations of pre-eclampsia. BJOG 2000;107:1410-6.
92. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002;7:51-61.